A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid
J. R. A. Kincaid, J. C. Caravez, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Risk factors for and pregnancy outcomes after SARS-CoV-2 in pregnancy according to disease severity: A nationwide cohort study with validation of the SARS-CoV-2 diagnosis of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)
A. J. M. Aabakke, T. G. Petersen, et al.
Collaboration in the time of COVID: a scientometric analysis of multidisciplinary SARS-CoV-2 research
E. Cunningham, B. Smyth, et al.
Characterizing and Predicting Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) in a Large Academic Medical Center in the US
L. G. Fritsche, W. Jin, et al.
Three Outbreaks of COVID-19 in a Single Nursing Home over Two Years of the SARS-CoV-2 Pandemic
V. Čokić, Z. Popovska, et al.
